PreciseDx

PreciseDx is a private, commercial-stage diagnostics company using artificial intelligence to transform cancer prognosis. Its core technology, the OncoIntelligence platform, analyzes digitized pathology slides to deliver a quantitative risk score for breast cancer recurrence in hours, addressing a critical bottleneck in current care pathways. The company targets the significant market of intermediate-grade breast cancer patients, offering a faster, more objective, and cost-effective alternative to traditional gene expression profiling. Founded in 2017 by renowned pathologist Dr. Carlos Cordon-Cardo, PreciseDx is positioned to improve clinical decision-making and patient anxiety by accelerating diagnostic clarity.

OncoIntelligence™: A proprietary AI/ML platform that performs quantitative morphometric analysis on standard digital pathology slides (H&E) to generate objective diagnostic and prognostic scores for cancer.

PreciseDx competes directly with gene expression test providers like Exact Sciences (Oncotype DX) and Myriad Genetics. It also competes in the broader digital pathology AI space with companies like Paige.AI, PathAI, and the AI divisions of large medtech firms (Roche, Philips), all developing algorithms for cancer diagnosis and prognosis.